4893 items matching your search terms.

A systematic review of performance-enhancing pharmacologicals and biotechnologies in the Army

Ko, H. Hunter, K. E. Scott, A. M. Ayson, M. Willson, M. L.
JOURNAL OF THE ROYAL ARMY MEDICAL CORPS, 2017     DOI:10.1136/jramc-2016-000752

Facilitating prospective registration of diagnostic accuracy studies: a STARD initiative

Korevaar, D. A. Hooft, L. Askie, L. M. Barbour, V. Faure, H. Gatsonis, C. A. Hunter, K. E. Kressel, H. Y. Lippman, H. McInnes, M. D. F. Moher, D. Rifai, N. Cohen, J. F. Bossuyt, P. M. M.
CLINICAL CHEMISTRY, 2017     DOI:10.1373/clinchem.2017.272765

Efficacy analysis of ABT-414 with or without temozolomide in patients with EGFR-amplified, recurrent glioblastoma from a multicenter, international phase I clinical trial

Lassman, A.B. Van Den Bent, M.J. Gan, H.K. Reardon, D.A. Kumthekar, P. Butowski, N.A. Lwin, Z. Mikkelsen, T. Nabors, L.B. Papadopoulos, K.P. Penas-Prado, M. Simes, J. Wheeler, H. Gomez, E.J. Lee, H.J. Roberts-rapp, L. Xiong, H. Bain, E.E. Maag, D. Merrell, R.T.

Assessing the benefits of anticancer drugs: update on the ASCO and ESMO value framework

Lawrence, N.

Predicted benefits of adjuvant sorafenib after nephrectomy for renal cell carcinoma in SORCE: an international, placebo-controlled, randomised phase 3 trial

Lawrence, N. Martin, A. Davis, I. Troon, S. Sengupta, S. Hovey, E. Coskinas, X. Kaplan, R. Ritchie, A. Meade, A. Eisen, T. Blinman, P. Stockler, M.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours

Leary, A. F. Quinn, M. Fujiwara, K. Coleman, R. L. Kohn, E. Sugiyama, T. Glasspool, R. Ray-Coquard, I. Colombo, N. Bacon, M. Zeimet, A. Westermann, A. Gomez-Garcia, E. Provencher, D. Welch, S. Small, W. Millan, D. Okamoto, A. Stuart, G. Ochiai, K. participants of the Fifth Ovarian Cancer Consensus, Conference
ANNALS OF ONCOLOGY, 2017     DOI:10.1093/annonc/mdw662

Phase I study of olaparib, in combination with oral cyclophosphamide, in patients with metastatic triple negative breast cancer and recurrent high grade serous ovarian cancer

Lee, C.K. Scott. C.L. Lindeman, G.J. Gibbs, E. Badger, H.D. Paterson R.J. Macnab, L. Kwan, E.M. Boyle, F.M. Friedlander, M. Australian and New Zealand Breast Cancer Trials Group (ANZ BCTG),

Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival

Lee, C. K. Davies, L. Wu, Y. L. Mitsudomi, T. Inoue, A. Rosell, R. Zhou, C. Nakagawa, K. Thongprasert, S. Fukuoka, M. Lord, S. Marschner, I. Tu, Y. K. Gralla, R. J. Gebski, V. Mok, T. Yang, J. C.
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017     DOI:10.1093/jnci/djw279

Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis

Lee, C. K. Man, J. Lord, S. Links, M. Gebski, V. Mok, T. Yang, J. C.
JOURNAL OF THORACIC ONCOLOGY, 2017     DOI:10.1016/j.jtho.2016.10.007

Resolution of acute food protein-induced enterocolitis syndrome in children

Lee, E. Campbell, D. E. Barnes, E. H. Mehr, S. S.
J ALLERGY CLIN IMMUNOL PRACT, 2017     DOI:10.1016/j.jaip.2016.09.032

Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer

Lee, Y. C. Bressel, M. Grant, P. Russell, P. Smith, C. Picken, S. Camm, S. Kiely, B. E. Milne, R. L. McLachlan, S. A. Hickey, M. Friedlander, M. L. Hopper, J. L. Phillips, K. A. Kathleen Cuningham Foundation Consortium for Research into Familial Breast, Cancer
FAM CANCER, 2017     DOI:10.1007/s10689-017-9977-x

Capecitabine and nab-paclitaxel as second-line treatment for advanced biliary tract cancer: results from a phase II pilot study

Leighton, C. Brungs, D. Sjoquist, K. Chantrill, L. Grimison, P. Tognela A. Aghmesheh, M.

TOPGEAR: A randomized, phase iii trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG

Leong, T. Smithers, B. M. Haustermans, K. Michael, M. Gebski, V. Miller, D. Zalcberg, J. Boussioutas, A. Findlay, M. O'Connell, R. L. Verghis, J. Willis, D. Kron, T. Crain, M. Murray, W. K. Lordick, F. Swallow, C. Darling, G. Simes, J. Wong, R.
ANNALS OF SURGICAL ONCOLOGY, 2017     DOI:10.1245/s10434-017-5830-6

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: is PTEN predictive of response?

Lester, A. Rapkins, R. Nixdorf, S. Khasraw, M. McDonald, K.
CLINICAL AND TRANSLATIONAL ONCOLOGY, 2017     DOI:10.1007/s12094-016-1547-4

Changes in gene expression of neo-squamous mucosa after endoscopic treatment for dysplastic Barrett's esophagus and intramucosal adenocarcinoma

Levert-Mignon, A. Bourke, M. J. Lord, S. J. Taylor, A. C. Wettstein, A. R. Edwards, M. Botelho, N. K. Sonson, R. Jayasekera, C. Fisher, O. M. Thomas, M. L. Macrae, F. Hussey, D. J. Watson, D. I. Lord, R. V.
, 2017     DOI:10.1177/2050640616650794